- Home
- NEWT vs SEPN Comparison
NEWT vs SEPN Comparison
Compare NEWT & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- SEPN
- Stock Information
- Founded
- NEWT 1998
- SEPN 2022
- Country
- NEWT United States
- SEPN United States
- Employees
- NEWT N/A
- SEPN N/A
- Industry
- NEWT Major Banks
- SEPN
- Sector
- NEWT Finance
- SEPN
- Exchange
- NEWT Nasdaq
- SEPN NYSE
- Market Cap
- NEWT 306.7M
- SEPN 311.6M
- IPO Year
- NEWT N/A
- SEPN 2024
- Fundamental
- Price
- NEWT $10.91
- SEPN $9.97
- Analyst Decision
- NEWT Hold
- SEPN Buy
- Analyst Count
- NEWT 4
- SEPN 4
- Target Price
- NEWT $14.00
- SEPN $27.00
- AVG Volume (30 Days)
- NEWT 262.1K
- SEPN 2.6M
- Earning Date
- NEWT 05-06-2025
- SEPN 05-15-2025
- Dividend Yield
- NEWT 6.98%
- SEPN N/A
- EPS Growth
- NEWT 27.62
- SEPN N/A
- EPS
- NEWT 1.92
- SEPN N/A
- Revenue
- NEWT $352,584,000.00
- SEPN $977,000.00
- Revenue This Year
- NEWT N/A
- SEPN N/A
- Revenue Next Year
- NEWT $16.83
- SEPN N/A
- P/E Ratio
- NEWT $5.66
- SEPN N/A
- Revenue Growth
- NEWT 23.06
- SEPN 108.76
- 52 Week Low
- NEWT $9.12
- SEPN $4.17
- 52 Week High
- NEWT $15.49
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- NEWT 50.75
- SEPN N/A
- Support Level
- NEWT $10.25
- SEPN N/A
- Resistance Level
- NEWT $11.15
- SEPN N/A
- Average True Range (ATR)
- NEWT 0.35
- SEPN 0.00
- MACD
- NEWT -0.00
- SEPN 0.00
- Stochastic Oscillator
- NEWT 45.83
- SEPN 0.00
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.